肺癌放疗患者心脏功能变化的前瞻性队列研究
该多中心前瞻性纵向队列纳入125例接受根治性胸部放疗的NSCLC患者,核心实验室定量分析基线与放疗后超声心动图。放疗后左室射血分数、整体纵向应变、圆周应变及Ea/Ees轻度恶化,多在12个月内恢复;7.2%患者出现临床相关心功能障碍,全心脏V30与LVEF下降相关。
要点
- 放疗后LVEF、整体纵向应变、圆周应变及Ea/Ees轻度恶化,多在12个月内恢复。
- 7.2%患者出现LVEF较基线下降≥10%且绝对值<50%的心功能障碍。
- 全心脏V30与LVEF下降独立相关,提示放疗计划中需关注该剂量体积指标。
核心结论
- NSCLC患者根治性胸部放疗后平均心脏功能变化轻微,但部分患者出现临床相关心功能障碍。
- 全心脏V30与LVEF下降相关,提示其在放疗计划中的参考价值,同时需要新的剂量体积指标。
研究设计与样本
- 多中心、纵向、前瞻性队列研究,纳入125例接受标准根治性胸部放疗的NSCLC患者。
- 从中心勾画的心脏亚结构中提取剂量体积指标,并在基线、放疗结束、放疗后6个月和12个月进行核心实验室定量的超声心动图检查。
- 采用广义估计方程进行重复测量多变量线性回归,估计超声心动图指标变化及其与剂量体积指标的关联。
主要发现
- 放疗后左室射血分数(p=0.019)、整体纵向应变(p<0.001)、圆周应变(p<0.001)和Ea/Ees(p=0.011)出现轻度恶化,多在12个月内恢复。
- 以LVEF较基线下降至少10%且阈值低于50%定义的心功能障碍发生率为7.2%,中位发生时间为放疗开始后1.7个月。
- 平均心脏剂量与LVEF下降相关(每四分位距增加-1.1%,95%CI:-2.2至0.0,p=0.044)。
- 全心脏V30与LVEF下降相关(每四分位距增加-1.4%,95%CI:-2.5至-0.3,p=0.015),多重比较校正后仍显著(p=0.030)。
临床怎么用
- 对接受根治性胸部放疗的NSCLC患者,应关注放疗后早期心脏功能变化,尤其LVEF下降。
- 放疗计划制定时可参考全心脏V30以降低LVEF下降风险,同时探索更优的剂量体积指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The cardiovascular toxicity of radiation therapy (RT) remains incompletely understood in patients with NSCLC. Our objective was to define changes in echocardiographic parameters of structure and function with RT and their associations with cardiac dose-volume metrics. METHODS: This multicenter, longitudinal, prospective cohort study included participants with NSCLC who received standard, curative-intent thoracic RT. Dose-volume metrics were extracted from centrally contoured cardiac substructures. Echocardiograms at baseline, end of RT, 6 months post-RT, and 12 months post-RT were core laboratory-quantified. Repeated-measures multivariable linear regression via generalized estimating equations estimated changes in echocardiographic measures and associations with dose-volume metrics. RESULTS: Across 125 participants, there was a modest worsening in left ventricular ejection fraction (LVEF) (p = 0.019), global longitudinal strain (p < 0.001), circumferential strain (p < 0.001), and Ea/Ees (p = 0.011) post-RT that largely recovered by 12 months. Cardiac dysfunction, defined as LVEF declines of at least 10% from baseline to a threshold value of less than 50%, occurred in 7.2% of participants at a median of 1.7 months after RT initiation. Mean heart dose was associated with LVEF declines (-1.1%, 95% confidence interval: -2.2 to 0.0 per interquartile range increase, p = 0.044), as was whole heart V30 (-1.4%, 95% confidence interval: -2.5 to -0.3 per interquartile range increase, p = 0.015); with multiple comparison adjustment, whole heart V30 remained significant (p = 0.030). CONCLUSIONS: On average, there were modest changes in cardiac function immediately after RT in patients with NSCLC, with a subset experiencing clinically relevant cardiac dysfunction. Although whole heart V30 was associated with LVEF declines, suggesting its relevance in RT planning, there is also a need for newer dose-volume measures.
引用
- Han IS, Ko K, Zou JW, et al. Changes in Cardiac Function in Patients Receiving Radiation Therapy for Lung Cancer. J Thorac Oncol. 2026. PMID: 41534787. doi:10.1016/j.jtho.2026.01.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。